|
Form 4 Oracle: Boston, MA -- Form4Oracle: Insider Trading Report: Enzo
Biochem Inc (ENZ)
(M2 PressWIRE Via Acquire Media NewsEdge)
RDATE:23072008
at Enzo Biochem Inc (ENZ) has reported buying -- today.Over the last
four weeks Rabbani Shahram K, Treasurer, Secretary has bought $1.10M
increasing overall holdings by 4%.
For a current, real-time summary of ENZ insider activity, visit
http://www.form4oracle.com/company?cik=0000316253&ticker=ENZ
About Form4Oracle
Form4Oracle, LLC specializes in distributing insider trading
information published by the SEC, making it accessible and actionable
for all types of investors. To learn more about how tracking insider
trading activity can improve your investment returns, visit
http://www.form4oracle.com.
About Enzo Biochem Inc
Enzo Biochem, Inc., a life sciences and biotechnology company, provides
diagnostic services to the medical community. The company operates in
three segments: Enzo Life Sciences, Enzo Therapeutics, and Enzo
Clinical Labs. The Enzo Life Sciences segment manufactures, develops
and markets biomedical research products and tools to research and
pharmaceutical customers world wide. It offers products applied in the
fields of gene expression, non-radioactive labeling and detection,
adipokines and obesity, apoptosis, cell cycle, cytoskeletal research,
DNA damage and repair, immunology and cancer research, inflammation,
neurobiology, nitric oxide and oxidative stress, and signal
transduction. The Enzo Therapeutics segment operates in the areas of
gastrointestinal, infectious, ophthalmic, and metabolic diseases. Its
therapeutic development programs include the HGTV43 gene medicine,
which is in preclinical studies, for use in the treatment of human
immunodeficiency virus; B27PD for the treatment of autoimmune uveitis;
Alequel, which completed a phase II randomized double-blind clinical
trial, for the treatment of treatment of Crohn's disease; EGS21 for the
for treatment of fatty liver leading to non alcoholic steatohepatitis;
Enzo-D58, which is in the preclinical development for the treatment of
osteoporosis and certain bone disorders; and EHT899 immune regulation
product, which completed preclinical animal studies, for the treatment
of hepatitis B virus. The Enzo Clinical Labs segment offers routine and
esoteric clinical laboratory tests or procedures used in general
patient care by physicians to establish or support a diagnosis, monitor
treatment or medication, and search for an otherwise undiagnosed
condition. It also operates a full-service clinical laboratory, a
network of 19 patient service centers, a stand alone or rapid response
laboratory, and a full-service phlebotomy department. The company was
founded in 1976 and is headquartered in New York, New York.
--------------------------------------------
The companies referenced in this report have not approved the
statements made in this report. This report contains statements that
imply risks and uncertainties. This material is for informational
reporting purposes only and should not be construed as an offer or
solicitation of an offer to buy or sell securities. Form4Oracle is not
a licensed broker, broker dealer, market maker, investment banker,
investment adviser, analyst or underwriter and is not compensated in
this regard.
Please consult your broker to understand investing benefits and risks
and prior to purchasing any securities mentioned herein.
CONTACT: Kimberly Sutton, Form4Oracle
Tel: +1 312 315 5077
e-mail: kimberly@form4oracle.com
WWW: http://www.form4oracle.com
((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).
Copyright ? 2008 M2 Communications Ltd.
[ Back To it.tmcnet.com's Homepage ]
|